|
a phase 2b randomised, double-blind, placebo-controlled, multi-centre, dose-ranging study of azd5718 in participants with proteinuric chronic kidney disease
|
24-01-202123-01-2024
|
Penyelidik Bersama
|
|
randomised, double-blind, placebo-controlled and parallel dose group trial to investigate efficacy and safety of multiple doses of oral bi 690517 over 14 weeks, alone and in combination with empagliflozin, in patients with diabetic and non-diabetic chroni
|
28-02-202227-10-2023
|
Penyelidik Bersama
|
|
height adjusted total kidney volume (httkv) using mri and age at httkv0 in predicting decline of renal function in malaysian autosomal dominant polycystic kidney disease (adpkd) cohort.
|
17-12-202016-12-2022
|
Penyelidik Bersama
|